GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Unipharma Co Ltd (ROCO:6621) » Definitions » Current Ratio

Unipharma Co (ROCO:6621) Current Ratio : 11.05 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Unipharma Co Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Unipharma Co's current ratio for the quarter that ended in Jun. 2024 was 11.05.

Unipharma Co has a current ratio of 11.05. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Unipharma Co's Current Ratio or its related term are showing as below:

ROCO:6621' s Current Ratio Range Over the Past 10 Years
Min: 5.23   Med: 8.22   Max: 11.96
Current: 11.05

During the past 11 years, Unipharma Co's highest Current Ratio was 11.96. The lowest was 5.23. And the median was 8.22.

ROCO:6621's Current Ratio is ranked better than
94.49% of 1035 companies
in the Drug Manufacturers industry
Industry Median: 1.97 vs ROCO:6621: 11.05

Unipharma Co Current Ratio Historical Data

The historical data trend for Unipharma Co's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unipharma Co Current Ratio Chart

Unipharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.77 9.60 5.59 8.28 6.10

Unipharma Co Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.87 8.28 8.37 6.10 11.05

Competitive Comparison of Unipharma Co's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unipharma Co's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's Current Ratio distribution charts can be found below:

* The bar in red indicates where Unipharma Co's Current Ratio falls into.



Unipharma Co Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Unipharma Co's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=226.228/37.116
=6.10

Unipharma Co's Current Ratio for the quarter that ended in Jun. 2024 is calculated as

Current Ratio (Q: Jun. 2024 )=Total Current Assets (Q: Jun. 2024 )/Total Current Liabilities (Q: Jun. 2024 )
=190.47/17.24
=11.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Unipharma Co  (ROCO:6621) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Unipharma Co Current Ratio Related Terms

Thank you for viewing the detailed overview of Unipharma Co's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Unipharma Co Business Description

Traded in Other Exchanges
N/A
Address
Jiu Zong Road, 3rd Floor, No. 17, Lane 171, Section 2, NeiHu District, Taipei, TWN, 11494
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.

Unipharma Co Headlines

No Headlines